Added to YB: 2024-01-05
Pitch date: 2024-01-05
ELYM [bullish]
Climb Bio, Inc.
+36.56%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.
Market Cap
$129.6M
Pitch Price
$2.79
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.82
P/E
-2.53
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
$ELYM: a new broken biotech
ELYM halts Ph2 ETX-155 on funding issues despite FDA nod; 55% layoff; pivots to preclin ETX-123 then stops R&D for strategic review; $100M cash no debt; 49% holder RA Cap may push rev merger; Chair Levin may value IP esp ETX-155; I hold shares
Read full article (1 min)